To further assess the consequences of SRSF2 mutation for the cellular proteome in myeloid neoplasms, we performed quantitative mass spectrometry (qMS) with a focus on the mitochondrial proteome by using human proteome (UniProtKB) and mitochondrial (MitoCarta3.0) databases for protein identification (Figure 6C). The gene discussed is SRSF2; the disease is myeloid neoplasm.